Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Rheumatoid Arthritis
How do you approach treatment of early onset RA with minimal peripheral disease and aggressive cervical atlantoaxial involvement?
RF/CCP negative, +hand synovitis on exam
Related Questions
For patients with obesity and elevated alk phos who have RA, do you check a fibroscan or serum NASH fibrosure test before starting methotrexate or leflunomide?
How do you approach venous insufficiency management in patients on Jak inhibitors?
Do you consider Anti-carbamylated protein antibodies (anti-CarP) as having any significance in evaluation of patients if RF and ACPA negative and clinically no active synovitis yet widespread arthralgias and generalized osteoarthritis?
Would you prescribe a JAK inhibitor in patients with baseline transaminase elevation?
How do you approach the timing of DMARD initiation in patients with active RA who are on treatment for latent TB?
What is your approach to treating Felty syndrome in a patient with well controlled synovitis on MTX/leflunomide with persistent neutropenia/cytopenias?
Do you avoid tocilizumab in patients with prior bariatric surgery given the risk of GI perforation?
Do you typically adjust or hold immunosuppression in a well-controlled RA patient who is being treated for Mycobacterium avium-intracellulare (MAI)?
Would you re-challenge a patient with Rituximab who responded well in terms of their RA but developed symptomatic tachycardia after their first infusion?
Does the presence of bronchiectasis change your approach to a patient with otherwise well-controlled patient with RA?